The Use of PCSK9 Inhibitor Is Associated With More Adaptative Eating Behaviors Among Adults With Heterozygous Familial Hypercholesterolemia

The Use of PCSK9 Inhibitor Is Associated With More Adaptative Eating Behaviors Among Adults With Heterozygous Familial Hypercholesterolemia

Saved in:

Bibliographic Details
Main Authors:	Clémence Desjardins, Marie-Pierre Gagnon-Girouard, Jacob Lessard-Lord, Valérie Guay, Maryka Rancourt-Bouchard, Patrick Couture, Anne Gangloff, Elise Carbonneau, Jean-Philippe Drouin-Chartier
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Current Developments in Nutrition
Online Access:	http://www.sciencedirect.com/science/article/pii/S2475299125019675
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia
Published: (2025-08-01)

ASSOTIATION OF THE GENETIC POLYMORPHISM E670G OF THE PCSK-9 AND THE SEVERITY OF THE CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN UZBEK POPULATION
by: R. B. Alieva, et al.
Published: (2019-09-01)

CASCADE GENETIC SCREENING IN DIAGNOSTICS OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: CLINICAL CASE
by: E. V. Shakhtshneider, et al.
Published: (2017-07-01)

In vivo adeno-associated virus-mediated LDLR/PCSK9 intervention for familial hypercholesterolemia
by: Zeyu Han, et al.
Published: (2025-11-01)

Phenotypical features of heterozygous familial hypercholesterolemia in individuals with LDLR or APOB gene mutations
by: A. N. Meshkov, et al.
Published: (1970-01-01)

Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
by: I. A. Alekseeva, et al.
Published: (2025-08-01)

Eating and Psychological Profiles of Women with Higher Depressive Symptoms Who Are Trying to Lose Weight
by: C. Bégin, et al.
Published: (2012-01-01)

Echocardiographic Calcium Score of Aortic Valve Correlates with Coronary Artery Calcium Score in Heterozygous Familial Hypercholesterolemia
by: Angelo Baldassare Cefalù, et al.
Published: (2025-03-01)

Phenotype of heterozygous familial hypercholesterolemia caused by deletion of <i>LDLR</i> gene exons 2-10: a case report
by: A. M. Moiseeva, et al.
Published: (2024-12-01)

Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study
by: Ana María González-Lleó, et al.
Published: (2025-08-01)

Severe hyperlipoproteinemia(a) as a factor of rapidly progressive coronary artery disease in a young woman with heterozygous familial hypercholesterolemia
by: U. V. Chubykina, et al.
Published: (2019-06-01)

New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia
by: Sushmitha Duddu, et al.
Published: (2025-01-01)

Sex and racial differences in prevalence and clinical characteristics of people living with LDLR and PCSK9 familial hypercholesterolemia genetic variants: Data from the All of Us Research program
by: Jeffery Osei, et al.
Published: (2025-06-01)

Familial hypercholesterolemia
by: Pankaj Singhania, et al.
Published: (2022-05-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Therapeutic Strategies for Hypercholesterolemia
by: Georg Noll, et al.
Published: (2024-07-01)

Adolescents’ reports of parental objectification of others’ bodies are associated with their body image and eating behaviors
by: Carolanne Tanguay, et al.
Published: (2025-07-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

RHEUMATIC MANIFESTATIONS OF FAMILIAL HYPERCHOLESTEROLEMIA
by: Lyudmila Valeryevna Teplova, et al.
Published: (2012-10-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Current Evidence and Future Directions of PCSK9 Inhibition
by: Jiaqian Xu, et al.
Published: (2021-02-01)

Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer
by: Ann‐Charlotte Bergeron, et al.
Published: (2025-02-01)

Diagnostic Characteristics of Familial Hypercholesterolemia in Children
by: Dinara I. Sadykova, et al.
Published: (2020-06-01)

ECONOMIC BURDEN OF HYPERCHOLESTEROLEMIA IN THE RUSSIAN FEDERATION
by: A. V. Kontsevaya, et al.
Published: (2018-07-01)

Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
by: Chenrui Qi, et al.
Published: (2025-12-01)

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab
by: Su-Hyun Bae, et al.
Published: (2025-03-01)

Engineering chimeric PCSK9 for a vaccine against atherosclerosis
by: Špela Malenšek, et al.
Published: (2025-09-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

School-based universal screening for hypercholesterolemia in children
by: Chang-Hsien Yu, et al.
Published: (2022-07-01)

Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?
by: Z. D. Kobalava, et al.
Published: (2020-11-01)

Familial Hypercholesterolemia in Children. The Current State of the Problem
by: Dinara I. Sadykova, et al.
Published: (2023-07-01)

CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS)
by: S. A. Boytsov, et al.
Published: (2013-08-01)

RUSSIAN GUIDELINES ON FAMILIAL HYPERCHOLESTEROLEMIA DIAGNOSIS AND TREATMENT
by: article Editorial
Published: (2017-06-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)